Clinical Trial

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Protocol Amendment History 1 change
notable Trial sites expanded: 56 -> 61 locations 2026-04-18
Trial Details
NCT Number NCT06897475
Lead Sponsor Eli Lilly and Company
Conditions Type 2 Diabetes
Enrollment 240 participants
Start Date 2025-03-28
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06